MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Opiant Pharmaceuticals ROCE Ratio 2011-2026 | OPNT
Annual ROCE Ratio Opiant Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.01 | -4.14 | 31.47 | -108.34 | 106.8 | 328.6 | 223.52 | 678.23 | 1785.12 | 21.39 | 30888.4 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30888.4 | -108.34 | 3087.46 |
Quarterly ROCE Ratio Opiant Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -107.39 | -100.97 | -47.57 | -5.15 | 6.03 | 8.08 | 3.7 | -0.74 | -1.56 | 28.91 | 57.33 | 61.82 | 29.26 | 23.82 | -12.1 | -22.93 | -59.8 | 10.57 | -2.44 | 5.72 | 16.22 | -135.75 | -105.99 | 43.51 | 92.9 | 220.67 | 329.8 | 221.0 | 341.06 | 594.04 | 494.52 | 667.85 | 560.18 | 868.54 | 931.23 | 1420.3 | 1551.11 | 2492.5 | 2496.26 | 3291.78 | 3293.32 | 3778.04 | 5724.3 | 4601.36 | 3801.05 | 2033.62 | 377.07 | 1390.36 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5724.3 | -135.75 | 859.7 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M |  USA |
 |
Ocular Therapeutix
OCUL
|
-41.27 | $ 7.85 | -2.73 % | $ 1.47 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 19.59 | 0.31 % | $ 916 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Pfizer
PFE
|
10.69 | $ 27.4 | -0.63 % | $ 156 B | USA |
 |
Precigen
PGEN
|
-528.46 | $ 3.83 | -1.79 % | $ 1.2 B | USA |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.2 | $ 1.22 | -5.81 % | $ 311 M | Britain |
 |
ProQR Therapeutics N.V.
PRQR
|
-50.51 | $ 1.47 | -2.04 % | $ 99.5 M |  Niderland |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
PTC Therapeutics
PTCT
|
-422.25 | $ 66.68 | -0.48 % | $ 5.3 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-459.35 | $ 0.8 | 1.48 % | $ 428 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-212.83 | - | -3.03 % | $ 260 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
13.33 | $ 13.61 | -1.16 % | $ 2.26 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
11.45 | $ 750.41 | -0.84 % | $ 78.5 B | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-66.51 | $ 1.08 | -0.92 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
903.05 | - | - | $ 40.5 M | USA |
 |
REGENXBIO
RGNX
|
-156.91 | $ 7.98 | -3.39 % | $ 412 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Rigel Pharmaceuticals
RIGL
|
32.05 | $ 26.1 | -1.02 % | $ 469 M | USA |
 |
Relay Therapeutics
RLAY
|
-47.89 | $ 9.68 | -4.35 % | $ 1.38 B | USA |